Copyright
©The Author(s) 2005.
World J Gastroenterol. Sep 14, 2005; 11(34): 5283-5288
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5283
Published online Sep 14, 2005. doi: 10.3748/wjg.v11.i34.5283
Table 2 Risk factors for development of DLR among non-Hodgkin’s lymphoma patients with HBV reactivation during chemotherapy
DLR (-) | DLR (+) | |||||
Total | n | % | n | % | P | |
Number of patients | 31 | 16 | 51.6 | 15 | 48.4 | |
Age (yr) | ||||||
≤45 | 11 | 4 | 36.4 | 7 | 65.6 | 0.2734 |
>45 | 20 | 12 | 60 | 8 | 40 | |
Sex | ||||||
Female | 14 | 7 | 50 | 7 | 50 | 1 |
Male | 17 | 9 | 52.9 | 8 | 47.1 | |
GPT>10X | ||||||
Yes | 19 | 8 | 42.1 | 11 | 57.9 | 0.2734 |
No | 12 | 8 | 66.7 | 4 | 33.4 | |
HBeAg | ||||||
Present | 29 | 16 | 55.2 | 13 | 44.8 | 0.2258 |
Absent | 2 | 0 | 0 | 2 | 100 | |
HBV genotype C | ||||||
No | 21 | 13 | 61.9 | 8 | 38.1 | 0.0768 |
Yes | 7 | 1 | 14.3 | 6 | 85.7 | |
Unknown or mixed type | 3 | 2 | 66.7 | 1 | 33.3 | |
Total bilirubin >5 | ||||||
Yes | 5 | 1 | 20 | 4 | 80 | 0.1719 |
No | 26 | 15 | 57.7 | 11 | 42.3 | |
Peak HBV DNA >100X | ||||||
Yes | 18 | 9 | 50 | 9 | 50 | 1 |
No | 13 | 7 | 53.8 | 6 | 46.2 | |
Patterns of reactivation | ||||||
Transient | 16 | 10 | 62.5 | 6 | 37.5 | 0.508 |
Protracted/resolved | 5 | 3 | 60 | 2 | 40 | |
Protracted/unresolved | 5 | 1 | 20 | 4 | 80 | |
Multiple reactivation | 3 | 1 | 33.3 | 2 | 66.7 | |
Unknown | 2 | 1 | 50 | 1 | 50 |
- Citation: Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol 2005; 11(34): 5283-5288
- URL: https://www.wjgnet.com/1007-9327/full/v11/i34/5283.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i34.5283